-
Peritoneal Metastasis in Non-Small Cell Lung Cancer: A Systematic Review of Clinical Features, Molecular Profiles, Diagnostic Approaches, and Outcomes
19 Sep 2025 09:19 GMT
… to metastatic lung cancer complicated with … lung cancer independent of oncogene status. Lung Cancer. … lung cancer with peritoneal carcinomatosis effectively treated with docetaxel. Japanese J Lung Cancer … cell lung cancer by functional class. Lung Cancer. …
-
Japan’s MHLW approves Novocure’s Optune Lua to treat unresectable advanced/recurrent non-small cell lung cancer
16 Sep 2025 11:35 GMT
… /PD-L1 inhibitors or docetaxel alone (control arm) for patients … , assessed Optune Lua concurrently with docetaxel versus docetaxel alone.
Patients randomized to … -small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It …
-
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
15 Sep 2025 11:08 GMT
… Lua concurrently with docetaxel versus docetaxel alone.
Patients … -Small Cell Lung Cancer (NSCLC)
Lung cancer is the most … lung cancer (NSCLC) accounts for approximately 85% of all lung cancers … non-small cell lung cancer, malignant pleural mesothelioma …
-
WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care
12 Sep 2025 22:10 GMT
… 2025 World Conference on Lung Cancer (WCLC), experts from … exhibit updated findings in lung cancer therapy. Presenters and researchers … 6) among those who received docetaxel (n = 30; HR, … completely resected non-small cell lung cancer (NSCLC) patients: first …
-
Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC
10 Sep 2025 09:37 GMT
… cadonilimab in IO-resistant lung cancer. The cadonilimab combination … pulocimab for IO-resistant lung cancer. Additionally, ivonescimab (PD … within a year. Docetaxel is the standard therapy … potential in IO-resistant lung cancer, notably extending patient …
-
OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer
08 Sep 2025 12:00 GMT
… compared to docetaxel in squamous non-small cell lung cancer (sqNSCLC) … of the drug beyond lung cancers for other indications … cell lung cancer (NSCLC) Squamous cell non-small cell lung cancer makes … all lung cancers, and is the most common lung cancer found …
-
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
06 Sep 2025 09:08 GMT
… of Lung Cancer (IASLC) 2025 World Congress on Lung Cancer (WCLC … Non-Small Cell Lung Cancer
Worldwide, lung cancer is one of … molecular characteristics of lung cancers harboring EGFR exon … Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer …
-
Emerging Targets in Non-Small Cell Lung Cancer
06 Sep 2025 06:12 GMT
… lung cancer (NSCLC) represents approximately 85% of all lung cancer … investigator (docetaxel/ramucirumab, docetaxel, gemcitabine, … cell lung cancer: molecular … docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer …
-
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
11 Sep 2025 16:00 GMT
… for metastatic Non-Small Cell Lung Cancer following first-line chemo-immunotherapy … nivolumab or docetaxel in patients with Non-Small Cell Lung Cancer (NSCLC). The … in metastatic non-small-cell lung cancer (mNSCLC) progressing after first line …
-
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites cellules
11 Sep 2025 16:00 GMT
… avec nivolumab ou avec docétaxel chez des patients atteints … Tedopi® associé au docétaxel, ou docétaxel seul (bras de référence … in metastatic non-small-cell lung cancer (mNSCLC) progressing after … monothérapie en comparaison avec docétaxel dans l’étude pivot …
About
© 1995-2025